SCHEMBL790308

SCHEMBL790308

Fc1ccc(OP(=S)(Cl)Cl)cc1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
HPGD P15428 1/20 0.38
NFE2L2 Q16236 1/20 0.34
MAOB P27338 3/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
MAOA P21397 1/20 0.33
SOS1 Q07889 1/20 0.32
HSPB1 P04792 1/20 0.32
DRD2 P14416 1/20 0.32
DRD4 P21917 1/20 0.32
DRD3 P35462 1/20 0.32
APP P05067 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
MAPT P10636 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL789906 0.78 MEN1 (0.52) CYP1A2CYP2C9CYP2C19HPGDMAOB
SCHEMBL28913398 0.76 HPGD (0.38) CYP1A2CYP2C9CYP2C19HPGDNFE2L2
SCHEMBL790223 0.76 CYP3A4 (0.54) MEN1KMT2AMAPTNPSR1
SCHEMBL790225 0.76 CA1 (0.52) CYP2C19HPGDNPC1RAB9AMAPT
SCHEMBL1809191 0.76 CYP1A2 (0.47) CYP1A2CYP2C9CYP2C19HPGDNFE2L2
SCHEMBL789902 0.75 SRC (0.46) HPGDMEN1KMT2A
SCHEMBL1009702 0.74 CYP1A2 (0.50) CYP1A2CYP2C9CYP2C19HPGDNFE2L2
SCHEMBL8519279 0.73 CYP2C19 (0.45) CYP1A2CYP2C9CYP2C19HPGDMEN1
SCHEMBL790310 0.73 SOS1 (0.42) NPC1RAB9ASOS1APPMEN1
SCHEMBL11806179 0.71 MAPT (0.44) HPGDNPC1RAB9AAPPMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9278990-B2 Substituted nucleotide analogs ALIOS BIOPHARMA, INC. (US) 2016-03-08 US disclosed
US-9278990-B2 Substituted nucleotide analogs ALIOS BIOPHARMA, INC. (US) 2016-03-08 US disclosed
US-20150038451-A1 SUBSTITUTED NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. 2015-02-05 US disclosed
US-20150038451-A1 SUBSTITUTED NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. 2015-02-05 US disclosed
US-8871737-B2 Substituted nucleotide analogs ALIOS BIOPHARMA, INC. (US) 2014-10-28 US disclosed
US-8871737-B2 Substituted nucleotide analogs ALIOS BIOPHARMA, INC. (US) 2014-10-28 US disclosed
WO-2012040127-A1 SUBSTITUTED NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2012-03-29 WO disclosed
US-20120071434-A1 SUBSTITUTED NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2012-03-22 US disclosed
US-20120071434-A1 SUBSTITUTED NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071434-A1 SUBSTITUTED NUCLEOTIDE ANALOGS PNP, NUDT1, TYMP CYP1A2 4803/4885CYP2C9 4386/4885CYP2C19 4042/4885
US-20150038451-A1 SUBSTITUTED NUCLEOTIDE ANALOGS PNP, NUDT1, TYMP CYP1A2 4803/4885CYP2C9 4386/4885CYP2C19 4042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.